Optimal management of metastatic prostate cancer may involve the combination of androgen deprivation therapy (ADT) with novel oral androgen receptor signaling inhibitors (ARSIs) such as abiraterone, enzalutamide, and apalutamide. This evidence concerns the gene AR and metastatic prostate carcinoma.